IDIOPATHIC PULMONARY FIBROSIS (IPF)

This Phase 2 trial tests an oral drug called buloxibutid in 378 people with idiopathic pulmonary fibrosis (IPF), a lung-scarring disease. Over 52 weeks, researchers compare two doses of buloxibutid against a placebo to see if it can slow lung function decline. The study is double…

This pilot study tests whether home-based or video-supervised exercise programs are acceptable and helpful for people with chronic lung diseases like IPF, sarcoidosis, bronchiectasis, asthma, and other interstitial lung diseases. Fifty participants will be randomly assigned to on…

This study looks at how things in the environment and at work might affect people with interstitial lung diseases (a group of lung conditions). Researchers will ask 1,000 adults with a new diagnosis about their exposures to things like pollution, chemicals, and dust. The goal is …

This study follows 250 Italian adults with genetic forms of pulmonary fibrosis to see how their lung function changes over time. Researchers will track breathing tests and compare patients who receive immune-modulating drugs with those who do not. The goal is to understand how in…

This study follows 1,423 adults with idiopathic pulmonary fibrosis (IPF) for two years to learn how the disease progresses naturally. Researchers will track events like sudden worsening, hospital stays, and deaths. The goal is to better understand IPF patterns, not to test a new …